GET DAILY SIGNALSAcrivon Therapeutics (ACRV) Analyst Targets Signal +630% Upside Potential
Key Takeaways
- The central price target of $11 is the arithmetic mean of seven verified analyst price targets collected from firms including Maxim Group, Oppenheimer, Piper Sandler, H.C. Wainwright, Jefferies, Citizens JMP, and Gabelli.
- Individual targets span a wide range from roughly $7 to $19, reflecting genuine disagreement about how much of the pipeline's value is already de-risked.
- With shares trading near $1.50, reaching $11 would require roughly 630% upside, an exceptionally large move even for a clinical-stage biotechnology company.
- The strongest supports are positive ACR-368 Phase 2b endometrial cancer data, a second clinical asset (ACR-2316), and a cash runway into the fourth quarter of 2027.
- The biggest risks are binary clinical-trial outcomes, a lack of revenue, and the potential for shareholder dilution before any product is approved.
- You can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots for AI-driven tools designed to help spot opportunities and monitor changing market conditions.
Analyst Price Targets and Consensus View
ACRV, the ticker for Acrivon Therapeutics, Inc., is a clinical-stage precision oncology company rather than an ETF. Seven individual analyst price targets were reviewed: Maxim Group at $7, Oppenheimer at $8, Piper Sandler at $8, Gabelli at $8, Citizens JMP at $13, Jefferies at $14, and H.C. Wainwright at $19. The arithmetic mean is approximately $11, which is used here as the central target, with an approximate low-to-high range of $7 to $19.
Every firm cited carries a Buy, Outperform, or Overweight rating, which is why aggregators describe the analyst consensus as "Strong Buy." Yet the nearly threefold spread between the lowest and highest target signals that analysts are not aligned on valuation. Lower targets are generally tied to nearer-term, pipeline-specific assumptions, while H.C. Wainwright's $19 target reflects a multi-asset, platform-based view spanning ACR-368, ACR-2316, and the CDK11 program. Piper Sandler raised its target from $6 to $8 in early 2026, a modestly constructive revision rather than a dramatic reappraisal. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares recently trading around $1.50 and a market capitalization near $63 million, moving to $11 would require upside of roughly 630%. That is a very large move by any standard and effectively assumes the company's most important clinical programs continue to succeed. The path is not a smooth re-rating but a series of data-driven steps. ACR-368 (prexasertib), a CHK1/CHK2 inhibitor, is in a registrational-intent Phase 2b study in serous endometrial cancer, where interim data showed a 52% confirmed overall response rate. A prespecified interim analysis and data update from the all-comer serous arms is expected in the second half of 2026. ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced into randomized dose expansion with durable activity reported in heavily pretreated patients.
What Could Support a Move Toward the Target
The clearest catalyst is additional ACR-368 data that holds up or improves, which would strengthen the case for a registrational filing. A planned confirmatory Phase 3 trial is expected to initiate in the first half of 2027. ACR-2316 also offers a second shot on goal, with early responses in tumor types that have not responded to other WEE1 or PKMYT1 inhibitors. Financially, the company reported about $90 million in cash as of mid-2026, expected to fund operations into the fourth quarter of 2027, which reduces near-term dilution risk. The proprietary AP3 (Acrivon Predictive Precision Proteomics) platform underpins a broader discovery engine, and insiders, including the chief executive, have been reported buying shares.
What Could Prevent the Target From Being Reached
Acrivon generates no product revenue and posted a net loss of about $18 million in its most recent quarter. As a pre-commercial biotechnology company, its valuation rests almost entirely on clinical results, which are inherently binary. A disappointing ACR-368 interim analysis, a safety setback for ACR-2316, or a regulatory delay could compress the stock sharply. Even positive data would likely require substantial additional capital to fund a Phase 3 trial, introducing dilution risk. Small-cap biotech valuations are also highly sensitive to shifts in investor risk appetite and sector rotation, so the same fundamentals can be repriced dramatically across different market regimes.
Technical Levels and Market Structure
The stock's 52-week range is roughly $1.27 to $3.56, so even the lowest analyst target of $7 sits far above any historical trading zone. That means there are no meaningful chart-based resistance levels between the current price and the target; the gap is a function of fundamental uncertainty, not technical supply. The shares have trended in a broad range near the lower end of that band, and a durable catalyst would need to establish new highs well above the $3.50 area before any move toward the analyst-derived target becomes visible on a chart.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact period varies by firm and is not always disclosed. For ACRV, the decisive events are the ACR-368 Phase 2b interim analysis and data update expected in the second half of 2026, the initiation of the Phase 3 trial in the first half of 2027, further ACR-2316 dose-expansion data, and any financing activity. ACR-2316 dose-escalation results were also scheduled for presentation in November 2026. Investors should watch these milestones alongside changes in analyst targets and ratings, which can shift materially after each data readout.
Final Assessment
The $11 central target represents the average of seven analyst price targets spanning $7 to $19, a very wide range that underscores how much depends on clinical execution rather than on any consensus about fair value. Reaching it would require roughly 630% upside from the recent share price near $1.50, a move achievable only through a sustained run of positive catalysts across ACR-368 and ACR-2316. Favorable endometrial cancer data, a second clinical asset, and a cash runway into late 2027 provide a credible foundation, but binary trial risk, no revenue, and future dilution are substantial counterweights. The upcoming ACR-368 interim analysis and Phase 3 planning are the most important checkpoints. No analyst target is a guarantee, and the outcome will ultimately be decided by data rather than by forecasts.
Using Tickeron AI Daily Buy/Sell Signals in Practice
In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a useful layer of technical monitoring for names like ACRV where catalysts can shift sentiment quickly. The system scans thousands of stocks and generates signals based on market conditions and AI analysis, helping me stay on top of trends without replacing fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACRV's RSI Indicator ascends from oversold territory
The RSI Indicator for ACRV moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 64 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 31 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement